Showing 19 Results
NPC's "The Myth of Average" explores how patients, health care providers, insurers, and other decision-makers can better consider individual patient differences when navigating the complexities of…
To understand when and how individual treatment effects are examined, conducted and reported, this study evaluated existing multiperson N-of-1 studies, which can identify whether an intervention is…
NPC supported a survey of Medicaid medical and pharmacy directors to better understand how policy makers in the state Medicaid programs view comparative effectiveness research (CER) and how they use…
Distributed data network drug safety analyses are difficult to interpret in the face of heterogeneity, or individual treatment effects.
The concept of heterogeneity is explained and further explored via four articles published in the June 2014 issue of the Journal of Managed Care & Specialty Pharmacy: The Good, the Bad, and the…
Although researchers and health care providers widely recognize that individuals with stage IV prostate cancer react differently to treatments, the factors that impact treatment outcomes, including…
The National Pharmaceutical Council conducted its third annual survey of key health care stakeholders. The purpose was to set a baseline for where key stakeholders believe we are today on comparative…
This collaborative project was developed by the National Pharmaceutical Council, the Center for Medical Technology Policy, and Outcome, a Quintiles Company.
A survey by NPC and the Benfield Group found that one of the benefits employers are looking for from CER is more information about which treatments help with productivity.
Research considers how genetics can impact how well medicines will work in certain populations.